{
    "persona": "alt_right",
    "model": "llama2:70b-chat-q6_K",
    "topic": "healthcare",
    "language": "German",
    "text": "🚨💭 Newsflash! First long-term data on Atogepant for Migraine Prevention is out! 70% of patients achieved 50% reduction in monthly migraine days at weeks 13-16 and it's maintained over 48 weeks! 💯👍 Safety and tolerability data looks good too! 🙌🏼",
    "retrieved_source": "https://www.medscape.com/viewarticle/first-long-term-data-atogepant-migraine-prevention-2024a10007cb",
    "annotation": {
        "topic": null,
        "persona": null,
        "authenticity": null
    },
    "id": "732bdc4a6e103a26a827ba3e2f47c423441294a9f76ea1e6"
}